Applied Molecular Transport, Inc.

Going public has been a lucrative means of raising cash for hundreds of biopharmaceutical companies during the past few years, but with biotech stock valuations plummeting it has become increasingly d

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com